tamibarotene has been researched along with azacitidine in 1 studies
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (azacitidine) | Trials (azacitidine) | Recent Studies (post-2010) (azacitidine) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 7,474 | 479 | 3,782 |
| Protein | Taxonomy | tamibarotene (IC50) | azacitidine (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, K; Banos, A; Bixby, D; Braun, T; Carulli, J; Cluzeau, T; Cook, RJ; de Botton, S; Eaton, M; Fenaux, P; Fiore, C; Hodgson, G; Jurcic, JG; Kang-Fortner, Q; Kelly, MJ; Liesveld, JL; Madigan, K; McKeown, M; Paul, S; Rizzieri, DA; Roboz, GJ; Roth, DA; Rousselot, P; Savona, MR; Sekeres, MA; Stein, EM; Stephens, K; Vigil, C; Volkert, A | 1 |
1 other study(ies) available for tamibarotene and azacitidine
| Article | Year |
|---|---|
Targeting RARA overexpression with tamibarotene, a potent and selective RARĪ± agonist, is a novel approach in AML.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Retinoic Acid Receptor alpha | 2023 |